Condition
Deep-Vein Thrombosis
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 4 (1)
Trial Status
Completed4
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT01602432Withdrawn
Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients
NCT01602445Completed
Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism
NCT00245856Phase 4CompletedPrimary
Treatment of Upper Extremity Deep-Vein Thrombosis
NCT00252005Phase 2CompletedPrimary
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
NCT00314990Not ApplicableCompletedPrimary
VITRO-Trial. B Vitamins and the Secondary Prevention of Venous Thrombosis
Showing all 5 trials